Repligen (NASDAQ:RGEN) Raised to Buy at Wall Street Zen

Repligen (NASDAQ:RGEN) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

RGEN has been the topic of several other research reports. Canaccord Genuity Group cut their price target on Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research note on Wednesday, April 16th. Evercore ISI initiated coverage on Repligen in a research note on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price target on the stock. Royal Bank Of Canada cut their price target on Repligen from $202.00 to $189.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 30th. JPMorgan Chase & Co. cut their price target on Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 29th. Finally, HC Wainwright reiterated a “buy” rating and set a $180.00 target price on shares of Repligen in a research note on Monday, May 5th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Repligen presently has a consensus rating of “Moderate Buy” and an average target price of $173.25.

Repligen Stock Up 1.1%

Shares of NASDAQ:RGEN opened at $118.85 on Friday. Repligen has a 52-week low of $102.97 and a 52-week high of $182.52. The firm has a market capitalization of $6.68 billion, a P/E ratio of -264.11, a P/E/G ratio of 3.37 and a beta of 1.10. The stock has a 50 day moving average price of $128.71 and a 200-day moving average price of $141.94. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.28 EPS. As a group, equities research analysts anticipate that Repligen will post 1.72 EPS for the current fiscal year.

Institutional Trading of Repligen

Institutional investors have recently added to or reduced their stakes in the business. CIBC Asset Management Inc lifted its holdings in shares of Repligen by 5.0% during the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock valued at $246,000 after buying an additional 81 shares during the period. Alliance Wealth Advisors LLC UT lifted its holdings in shares of Repligen by 2.5% during the 1st quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 89 shares during the period. Utah Retirement Systems lifted its holdings in shares of Repligen by 1.1% during the 4th quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company’s stock valued at $1,338,000 after buying an additional 100 shares during the period. State of Michigan Retirement System lifted its holdings in shares of Repligen by 0.8% during the 1st quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock valued at $1,585,000 after buying an additional 100 shares during the period. Finally, Louisiana State Employees Retirement System lifted its holdings in shares of Repligen by 0.7% during the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company’s stock valued at $1,858,000 after buying an additional 100 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.